Abstract 1269P
Background
The rate of lung cancer recurrence following curative surgical resection is 30-55% and remains a significant challenge in patient management. Accurate prediction of recurrence risk is crucial for guiding treatment decisions, such as the use of (neo-)adjuvant chemo- or immunotherapy, the extent of lung resection, and follow-up strategies. We present a preoperative machine learning model that uses patient computed tomography (CT) images and demographic features to predict lung cancer recurrence.
Methods
We collected a dataset of 588 clinical stage I-IIIA lung cancer patients who underwent surgical treatment for lung cancer, of which 147 had lung cancer recurrence. This includes retrospectively collected CT images and associated demographic and pathological data from patients in both screening and clinical settings from the US National Lung Screening Trial (NLST) and the North Estonia Medical Centre (NEMC). The preoperative model was trained to predict the likelihood of recurrence on a diverse set of features, including radiomic features extracted from CT images and relevant clinical variables. An 8-fold cross validation strategy was used, where, in each fold, 6 (of the 8 equally sized) subsets were used for training, one for model tuning, and one for validation. As a baseline, we compare the preoperative model to ranked clinical staging. Performance was evaluated using the Area-Under-the-ROC-Curve (AUC), sensitivity, and specificity.
Results
Lung cancer recurrence prediction results are tabulated below. We find that our model performs significantly better (AUC=61.4, Sen=18.2) than preoperative staging alone (AUC=56.1, Sen=16.4, p-value=0.035). Table: 1269P
AUC, sensitivity and specificity performance of our machine learning model compared with ranked TNM staging. The specificity is set to 90.0 for a rule-in context
Predictors | AUC | Sensitivity | Specificity |
TNM | 56.1 (51.1, 61.2) | 16.4 (10.1, 23.6) | 90.0 |
Our model | 61.4 (56.7, 66.3) | 18.2 (10.2, 24.5) | 90.0 |
Conclusions
Based on this retrospective analysis, we find that our model outperforms clinical staging prediction of lung cancer recurrence in preoperative settings. With further development, this algorithm could prove a valuable tool to aid the management of lung cancer patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Optellum.
Funding
Optellum.
Disclosure
A. Gasimova, N. Waterfield Price, L. Freitag: Financial Interests, Personal, Full or part-time Employment: Optellum. All other authors have declared no conflicts of interest.
Resources from the same session
1288P - Neoadjuvant therapy with anti-PD-1/PD-L1 plus platinum-base chemotherapy for resectable stage II-III non-small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
Presenter: Maria Dacoregio
Session: Poster session 04
1289TiP - LANTERN study: A multi-omics digital human avatar for integrating precision medicine into clinical practice for lung cancer patients
Presenter: Emilio Bria
Session: Poster session 04
1294P - A final analysis of a phase II study of durvalumab immediately after completion of chemoradiotherapy in unresectable stage III non–small-cell lung cancer: TORG1937 (DATE study)
Presenter: Tetsuro Kondo
Session: Poster session 04
1296P - Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial
Presenter: Wei Guo
Session: Poster session 04
1297P - An open-label, prospective phase II study of tislelizumab in combination with chidamide as consolidation therapy in locally advanced, unresectable, stage III NSCLC
Presenter: Yi Hu
Session: Poster session 04
1298P - Chemotherapy with concurrent proton vs. photon radiotherapy in stage III NSCLC: Effects on hematological toxicity and immune therapy
Presenter: Francesco Cortiula
Session: Poster session 04
1299P - The role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study
Presenter: Lingjuan Chen
Session: Poster session 04
1300P - Treatment and clinical outcome in recurrent/refractory locally advanced NSCLC following chemoradiotherapy and consolidative durvalumab
Presenter: Georg Evers
Session: Poster session 04